Arcus Biosciences Inc - RCUS STOCK NEWS

Arcus Biosciences, Inc. granted new employees options to purchase 18,400 shares of common stock and restricted stock units for 9,200 shares. The exercise price per share was $16.47, based on the closing price on March 25, 2024. The equity awards were issued under the 2020 Inducement Plan.

Arcus Biosciences, Inc. (NYSE:RCUS) granted new employees options to purchase 13,800 shares of common stock and restricted stock units for 6,900 shares. The awards were granted under the 2020 Inducement Plan at an exercise price of $17.99 per share.

Arcus Biosciences (RCUS) will participate in investor conferences in March 2024, including Leerink Global Biopharma Conference and Barclays Global Healthcare Conference. The company aims to showcase its differentiated molecules and combination therapies for cancer patients.

Arcus Biosciences, Inc. granted new employees options to purchase 17,600 shares of common stock and restricted stock units for 8,800 shares. The exercise price per share was $19.53, based on the closing price on February 26, 2024.

Arcus Biosciences, Inc. and Gilead announce additional equity investment and modifications to clinical programs, with positive data supporting potential for casdatifan. Arcus reports financial results for Q4 2023, highlighting $1.2 billion in pro forma cash. The company plans six ongoing Phase 3 trials for three distinct programs and has cash runway into 2027. Key partnerships and pipeline updates are detailed in the PR.

Arcus Biosciences, Inc. (RCUS) granted new employees options to purchase 71,900 shares at $15.20 per share and restricted stock units for 35,950 shares. The equity awards were granted under the 2020 Inducement Plan.

Arcus Biosciences (NYSE:RCUS) will host a conference call and webcast to discuss pipeline updates and financial results for the quarter and year ended December 31st, 2023. The event will take place on February 21, 2024, at 2:00 PM PT / 5:00 PM ET. Investors can listen to the conference call by dialing (404) 975-4839 (local) or (833) 470-1428 (toll-free) using Access Code: 235272. The live webcast and slide presentation will be available on the company's website at www.arcusbio.com, with a replay available after the event.

Gilead Sciences, Inc. and Arcus Biosciences, Inc. have announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share. The investment reinforces the companies' conviction in the TIGIT pathway and provides an opportunity to accelerate the anti-TIGIT program. The amendment also provides Gilead with one additional seat on the Arcus Board. The press release highlights the governance enhancements enabling streamlined decision-making and reflects the continued growth of the collaboration. Gilead and Arcus have reprioritized the joint domvanalimab development program to focus on advancing and potentially accelerating the Phase 3 studies STAR-121 (lung cancer) and STAR-221 (gastrointestinal cancer). This prioritization reflects the companies' continued conviction in the TIGIT pathway and the Fc-silent design of domvanalimab, which has the potential for differentiation in both efficacy and safety. The additional investment by Gilead, which extends Arcus' cash runway into 2027, will enable the funding of Phase 3 studies of quemliclustat in pancreatic cancer and AB521 in kidney cancer, as well as the preparation for potential product approvals.

Gilead Sciences, Inc. invests $320 million in Arcus Biosciences, Inc. and amends collaboration agreement, raising Gilead's ownership stake in Arcus to 33%. The investment aims to accelerate the joint development programs, with a focus on advancing Phase 3 studies for lung and gastrointestinal cancers. The amendment also provides Gilead with one additional seat on the Arcus Board, enabling streamlined decision-making.